← Back to Analyst Consensus 
TBPH Hold
Theravance Biopharma, Inc.
Current Price —
Implied Upside —
Analysts 11
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Next Earnings
Nov 9, 2026 (13 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Jul 7, 2026 | HC Wainwright & Co. | downgrade | Buy → Neutral | — | 44% |
| Jun 29, 2026 | Jones Trading | downgrade | Buy → Hold | — | 50% |
| Jun 29, 2026 | BTIG | downgrade | Buy → Neutral | — | 52% |
| Apr 7, 2026 | B. Riley Securities | maintain | Neutral → Neutral | — | 54% |
| Mar 23, 2026 | TD Cowen | maintain | Hold → Hold | — | 54% |
| Mar 20, 2026 | BTIG | reiterate | Buy → Buy | — | 52% |
| Mar 5, 2026 | Oppenheimer | downgrade | Outperform → Perform | — | 52% |
| Mar 4, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Mar 4, 2026 | B. Riley Securities | downgrade | Buy → Neutral | — | 54% |
| Mar 3, 2026 | BTIG | maintain | Buy → Buy | — | 52% |
| Mar 2, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Feb 3, 2026 | BTIG | reiterate | Buy → Buy | $40 | 52% |
| Dec 3, 2025 | Oppenheimer | initiate | — → Outperform | $27 | 52% |
| Nov 26, 2025 | BTIG | maintain | Buy → Buy | $40 | 52% |
| Nov 11, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $20 | 44% |
| Sep 12, 2025 | B. Riley Securities | initiate | — → Buy | $28 | 54% |
| Jun 27, 2025 | BTIG | maintain | Buy → Buy | $25 | 52% |
| Jun 17, 2025 | Jones Trading | initiate | — → Buy | $24 | 50% |
| Feb 27, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $15 | 44% |
| Feb 25, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $15 | 44% |
| Sep 16, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $15 | 44% |
| Aug 6, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $15 | 44% |
| Aug 6, 2024 | TD Cowen | maintain | Hold → Hold | $9 | 54% |
| Aug 6, 2024 | Leerink Partners | downgrade | Outperform → Market Perform | $10 | 51% |
| May 29, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $20 | 44% |
| May 14, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $20 | 44% |
| Apr 12, 2024 | BTIG | initiate | — → Buy | $21 | 52% |
| Aug 8, 2023 | HC Wainwright & Co. | reiterate | Buy → Buy | $20 | 44% |
| May 9, 2023 | HC Wainwright & Co. | maintain | — → Buy | $20 | 44% |
| Feb 28, 2023 | HC Wainwright & Co. | reiterate | — → Buy | $19 | 44% |
| Nov 17, 2022 | SVB Leerink | maintain | — → Outperform | $14 | — |
| Nov 8, 2022 | HC Wainwright & Co. | maintain | — → Buy | $19 | 44% |
| Jul 25, 2022 | Morgan Stanley | maintain | — → Underweight | $10 | 54% |
| May 23, 2022 | SVB Leerink | initiate | — → Outperform | $12 | — |
| Mar 2, 2022 | Morgan Stanley | maintain | — → Underweight | $11 | 54% |
| Feb 24, 2022 | HC Wainwright & Co. | maintain | — → Buy | $12 | 44% |
| Nov 5, 2021 | JP Morgan | upgrade | Underweight → Neutral | $12 | 55% |
| Sep 16, 2021 | Morgan Stanley | maintain | — → Underweight | $10 | 54% |
| Sep 16, 2021 | HC Wainwright & Co. | maintain | — → Buy | $8 | 44% |
| Sep 16, 2021 | SVB Leerink | maintain | — → Outperform | $10 | — |
| Aug 25, 2021 | Morgan Stanley | downgrade | Overweight → Underweight | $14 | 54% |
| Aug 24, 2021 | Cowen & Co. | downgrade | Outperform → Market Perform | $14 | — |
| Aug 24, 2021 | SVB Leerink | maintain | — → Outperform | $29 | — |
| Aug 24, 2021 | Needham | maintain | — → Buy | $18 | 50% |
| Aug 24, 2021 | HC Wainwright & Co. | maintain | — → Buy | $21 | 44% |
| Aug 4, 2021 | SVB Leerink | maintain | — → Outperform | $37 | — |
| Jul 16, 2021 | Morgan Stanley | maintain | — → Overweight | $27 | 54% |
| Jun 28, 2021 | SVB Leerink | maintain | — → Outperform | $36 | — |
| May 13, 2021 | Morgan Stanley | maintain | — → Overweight | $28 | 54% |
| May 5, 2021 | Needham | maintain | — → Buy | $32 | 50% |
Price Target Trend
May 22, 2026 Oct 26, 2026
EPS Estimates
+1q —
+1y —
0y —
0q —
Cross-Platform Signals
No cross-platform signals in the last 90 days